Product image of Icatibant Stada (Icatibant) supplied by GNH India

Icatibant Stada

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Stada (Icatibant)

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and II in patients with confirmed diagnosis.

GNH India supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product delivery across regulated markets.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

  • Acute hereditary angioedema type I: rapid reduction of subcutaneous and airway edema.
  • Acute hereditary angioedema type II: prompt relief of swelling episodes.
  • Hereditary angioedema attacks related to C1‑esterase inhibitor deficiency: improves airway patency and reduces pain.

How It Works

  • Icatibant selectively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin‑induced vasodilation and increased vascular permeability. By inhibiting this receptor, the drug reduces the plasma leakage that causes the swelling characteristic of hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: transient edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Angioedema: new swelling episodes unrelated to HAE.
  • Urticaria: hives or skin rash.
  • Hypotension: sudden drop in blood pressure.
  • Severe injection‑site necrosis: tissue damage at the site.
  • Thrombotic events: rare clot formation.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Hypersensitivity: do not use in patients with known allergy to icatibant or any excipients.
  • Pregnancy: consult a healthcare professional; safety data are limited.
  • Breastfeeding: use with caution; it is unknown whether the drug passes into breast milk.
  • Renal impairment: consider dose adjustment and monitor renal function.
  • Concomitant ACE inhibitors: monitor for enhanced bradykinin effects.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medicines that influence bradykinin levels or vascular tone.

Major Interactions (Avoid)

  • ACE inhibitors: may increase bradykinin‑mediated effects, raising risk of angioedema.
  • Neprilysin inhibitors: elevate bradykinin concentrations, potentially reducing efficacy.
  • C1‑esterase inhibitor concentrates: concurrent use may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing oral contraceptives: may increase frequency of HAE attacks.
  • Diuretics: can affect fluid balance; monitor blood pressure.
  • Other subcutaneous biologics: observe for overlapping injection‑site reactions.

Frequently Asked Questions

Icatibant Stada is used to treat acute attacks of hereditary angioedema (HAE) types I and II. It works by rapidly reducing swelling in the skin, gastrointestinal tract, and airway, providing relief from the painful and potentially life‑threatening symptoms of HAE episodes.

Icatibant is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema attacks.

The dose of Icatibant Stada is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidance. The prescriber will decide the exact amount, frequency, and duration of treatment for each individual attack.

Safety data for Icatibant Stada in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the medication.

To order Icatibant Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternatives for acute HAE attacks are C1‑esterase inhibitor concentrates and the kallikrein inhibitor ecallantide. Icatibant targets the bradykinin B2 receptor directly, offering a rapid subcutaneous option, whereas C1‑esterase inhibitors are administered intravenously and ecallantide is given subcutaneously but works upstream in the kallikrein‑kinin pathway.

Icatibant Stada should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection can be performed by a healthcare professional or, after proper training, by the patient or a caregiver. The medication is supplied in a pre‑filled syringe or vial for single‑use administration.

Serious risks include anaphylaxis, severe hypersensitivity reactions, new onset angioedema unrelated to HAE, and hypotension. Patients should be monitored closely after the first dose, and any signs of severe allergic reaction or sudden drop in blood pressure require immediate medical attention.

Icatibant Stada is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is advised for patients with severe renal impairment, and it should be used only under medical supervision in pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT